<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref131">
 <mixed-citation publication-type="book">
  <person-group person-group-type="author">
   <name>
    <surname>Sivapalasingam</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Caballero-Perez</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Houghton</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Davis</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Gao</surname>
    <given-names>B.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2015</year>). “
  <article-title>Phase 1 study evaluating safety, tolerability, pharmacokinetics and immunogenicity of REGN2222 in healthy adults: a new human monoclonal RSV-F antibody for RSV prevention</article-title>” in 
  <source>Open forum infectious diseases</source> (
  <publisher-loc>San Diego, CA</publisher-loc>: 
  <publisher-name>Oxford University Press</publisher-name>).
 </mixed-citation>
</ref>
